Table 1.

Randomized clinical trials, ongoing and completed, for Group 1 PAH

Deug	Administration	Mechanism of action	Primary endpoint	Trial Phase	Ongoing /completed
Sotatercept	Subcutaneous/ Every 3 weeks	Traps activins and growth differentiation factors	1) change from baseline to week 24 in pulmonary vascular resistance 2) change from baseline at week 24 in the 6-minute walk distance	1) Phase 2 (PULSAR) 2)Phase 3 (STELLAR	Completed
Seralutinib	Inhalation/ BID	inhibition of PDGFRα/β, CSF1R, and c-KIT	Change from baseline to Week 24 in pulmonary vascular resistance by right heart catheterization	Phase 2	Completed
Imatinib	Inhalation/ BID	Inhibition of tyrosine kinase involved in growth, differentiation, proliferation, survival, inflammation, metabolism and apoptosis	1) Phase 2b: placebo corrected change in pulmonary vascular resistance (PVR) 2) Phase 3: placebo corrected change in 6- minute walk distance (6MWD)	1)Phase 2b 2) Phase 3	Ongoing
Treprostinil Palmitil	Inhalation/ OD	Increase of the prostacyclin effect on receptors	Change from baseline to Week 16 in PVR	Phase 2b	Ongoing